- Alovudine
- ALVAC 1433
- AMD070
- AV-1101
- AVX754
- Azodicarbonamide (ADA)
- BMS-488043
- Brecanavir
- Buspirone hydrochloride (Buspar)
- Calanolide A
- Calcium spirulan
- CD4-based therapies
- Cell Genesys gene therapy
- Cimetidine (Dyspamet / Tagamet)
- Colony stimulating factors
- Curcumin
- Dapivirine
- Dextran sulphate
- Dinitrochlorobenzene (DNCB)
- Elvucitabine
- Etravirine
- Extracorporeal photopheresis
- FP-21399
- GPG-NH2
- GS 9137
- GW695634
- GW8248
- HEPT derivatives
- HGP-30
- HGTV43
- Hydroxycarbamide (Hydrea)
- Hyperthermia
- Interferon gamma-1b (Immukin)
- Interleukin-12
- Interleukin-16
- Intravenous immunoglobulin
- Iscador
- Isoprinosine
- JE-2147
- Lentinan
- Malariotherapy
- Maraviroc
- MIV 150
- MK-0518
- MVA-BN-Nef vaccine
- Mycophenolate mofetil (CellCept)
- Ozone
- P-1946
- p24.VLP
- PA-457
- Passive immunotherapy
- Phosphazid
- PN355
- PRO 2000
- PRO 542
- pTHr.HIVA
- Racivir
- Remune
- S-1360
- SJ-3366
- SP1093V
- SPV-30
- Stampidine
- T-1249
- Tat toxoid vaccine
- Thymic peptides
- TMC278
- TNFR:Fc
- TNX-355
- Todoxin
- TSAO derivatives
- Tucaresol
- Vesnarinone
- Vicriviroc
- VIR201
- Virodene P058
- WF10
Virodene P058
Virodene P058 is an experimental treatment developed by researchers in Pretoria, South Africa.
Virodene is composed of dimethylformamide (DMF), an industrial solvent used in cryopreservation (preserving body tissues by lower the body temperature). However, there appears to be little or no evidence that DMF has any direct antiviral effects, and there is no research to support the specific claim that it inhibits HIV's protease enzyme.
It was the centre of controversy in early 1997 after preliminary, uncontrolled findings based on seven recipients were presented to the South African cabinet, rather than through standard mechanisms of medical peer review, resulting in newspaper reports of a treatment 'breakthrough'. In the study, participants were treated with Virodene in the form of a patch, from which the chemical was absorbed through the skin.
There is evidence that DMF can cause liver damage when taken by mouth and when DMF is used in industrial settings, it is recommended to avoid exposure of the skin to the quantities used in this study.
latest aidsmap news
- Microbicide and PrEP potential for anal sex explored further in monkey studies
- ‘Shocking’ rates of adverse events seen with traditional and medical circumcision in Kenya
- Brazil rejects tenofovir patent
- Fibrosis linked to rapid loss of gut CD4 cells after HIV infection
- Poor results using non-medical HIV counsellors to screen for treatment eligibility in Malawi
- Raltegravir may cause temporary worsening of pre-existing depression
- Etravirine (<i>Intelence</i>) approved in Europe for treatment-experienced patients
- Belief in conspiracy theories means less HIV testing in South Africa
- Case report - viral load undetectable in blood, but detectable in semen
- Blood viral load predicts HIV transmission better than semen viral load in small study among MSM
